• Home
  • Drug utilization study Publications

Drug utilization study Publications

Drug utilization study Publications

  • Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study.Abstract

    BACKGROUND: The expiration of patents of brand inhalation medications and the ongoing pressure on healthcare budgets resulted in a growing market for generics. AIM: To study the use of brand and generic inhalation medication and the frequency of swtching between brand and generic and between devices

    Engelkes M, van Blijder veen JC, Overbeek JA, Kuiper J, Herings RCM, Sturkenboom Mcjm, deJongste JC, Verhamme KMC, Janssens HM. J Asthma. 2018 Nov 29; 55 1086-1094.
  • Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes.Abstract

    AIM: This study explores the changes in glucose-lowering drug (GLD) use before and after cancer diagnosis among patients with diabetes. METHODS: New GLD users (1998-2011) living in the Dutch ECR-PHARMO catchment area were selected from the PHARMO Dtabase Network (n=52,228). Those with a primary cancer diagnosis were considered cases (n=3281) and matched with eligible controls (n=12,891) without cancer during follow-up

    Zander s MMJ, Haak HR, van Herk-Sukel MPP, Herings RMC, van dePoll-Franse LV, Johnson JA. Diabetes Metab. 2018 Oct 21; 44 22 - 29.
  • Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.Abstract

    PURPOSE: The aim of this analysis was to identify factors associated with the choice of type 2 diabetes mellitus (T2DM) therapy at the time of intensification of antidiabetic treatment across 4 European countries. METHODS: Antidiabetic drug prescrition/dispensing records and patients’ characteristics were obtained from the electronic health care records of patients with T2DM from the Netherlands (NL), Italy, and Spain (ES) (all, 2007-2011); and the United Kingdom (UK; 2008-2012)

    Heintjes EM, Overbeek JA, Hall GC, Prieto-Alhambra D, Lapi F, Hammar N, Bezemer ID. Clin Ther. 2017 Nov 03; 39 2296-2310.
  • Thrombotic risk minimization for Diane-35 and generics.Abstract

    BACKGROUND: This study aimed to evaluate the effect of risk minimization measures on cyproterone acetate/ethinylestradiol (CPA/EE) use in the Netherlands. Potential indications of use and concomitant pharmacy dispensing of other hormonal contraceptves (HC) were assessed among new users in 2011, 2012, and 2014

    Bezemer ID, Smits E, Penning-van Beest FJA, Asiimwe A, Herings RMC. Pharmacoepidemiol Drug Saf. 2017 Sep 26; 26 1411-1417.
  • Ophthalmic nepafenac use in the Netherlands and Denmark.Abstract

    PURPOSE: To describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac. METHODS: We identified users in the PHARMO Database Network (the Netherands, 2008-2013) and the Danish national health registers (Denmark, 1994-2014)

    Margulis AV, Houben E, Hallas J, Overbeek JA, Pottegard A, Torp-Peder sen T, Perez-Gutthann S, Arana A. Acta Ophthalmol. 2017 Aug; 95 509-517.
  • Decrease in Switches to ‘Unsafe’ Proton Pump Inhibitors After Communications About Interactions with Clopidogrel.Abstract

    BACKGROUND: In 2009 and 2010 medicines regulatory agencies published official safety statements regarding the concomitant use of proton pump inhibitors and clopidogrel. We wanted to investigate a change in prescription behaviour in prevalent gastrorotective drug users (2008-2011). METHODS: Data on drug use were retrieved from the Out-patient Pharmacy Database of the PHARMO Database Network

    Kruik-Kolloffel WJ, van der Palen J, van Herk-Sukel MPP, Kruik HJ, Movig KLL. Clin Drug Investig. 2017 Aug; 37 787-794.
  • Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.Abstract

    OBJECTIVE: To describe the characteristics of pediatric patients prescribed proton pump inhibitors (PPIs) vs those of pediatric patients prescribed histamine-2-receptor antagonists (H2RAs). METHODS: Observational studies were conducted using The Helth Improvement Network (THIN) and the PHARMO Database Network

    Ruigomez A, Kool-Houweling LMA, Garcia Rodriguez LA, Penning-van Beest FJA, Herings RMC. Curr Med Res Opin. 2017 Jun 09; 33 2251-2259.
  • Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study.Abstract

    BACKGROUND: Several studies showed a bidirectional association between type 2 diabetes and psychiatric disorders in adults. Because there is limited information on the association between type 1 diabetes (T1D) and psychiatric disorders (including pychiatric medication use) in children and adolescents, we assessed frequency of use of these medications before and after the onset of T1D

    FazeliFarsani S, Abdullah-Koolmees H, Souverein PC, de Boer A, Mantel-Teeuwisse AK. Pediatr Diabetes. 2017 Apr 24; 121 - 128.
  • Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-Based Multi-Database Study.Abstract

    PURPOSE: The aim of this study was to determine the similarities and differences of type 2 diabetes mellitus (T2DM) treatment patterns in daily practice in 5 European countries and whether these reflect differences in guidelines. METHODS: Prescriptons for drugs used in diabetes treatment during a 5-year study period were obtained from electronic databases

    Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RM. Clin Ther. 2017 Mar 22; 39 759-770.
  • Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands.Abstract

    PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C meaurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemicstroke, peripheral arterial disease, and diabetes mellitus

    Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJ, Khan I, van Riemsdijk M, Herings RM. Clin Ther. 2017 Mar 24; 819 - 827.